Clinical trials: Acute Cardiovascular Disease
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Stroke, Acute
Efficacy of Adhesive Strength of New Hydrogel Formulation
The study will look at the stickiness of a new skin adhesive incorporated into a new next generation geko™ device called the geko™ X-T3 and compare it to the adhesive currently used into the geko™ T3 device.
- Trial name
- NCT04309110
- Testing
- or geko™ X-T3
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Firstkind Ltd
Myocardial Ischemia, Hypertension
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
Primary Objective The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in…
- Trial name
- NCT00296218
- Testing
- Irbesartan
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 440 people
- Sponsor
- Sanofi
Aortic Dissection
Zenith® Dissection Clinical Trial
The Zenith® Dissection Clinical Trial is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of acute, complicate Type B aortic dissection.
- Trial name
- NCT01568320
- Testing
- Endovascular Treatment (Zenith)
- Where
- 24 sites in United States, Japan
- Volunteers
- 73 people
- Sponsor
- Cook Research Incorporated
Acute Ischemic Stroke
Neuroprotection in Acute Cerebral Ischemia II
The goal of this clinical trial is to evaluate whether low-frequency, low-intensity transcranial magnetic stimulation (ELF-MF), delivered by the I-NIC medical device, is effective and safe in treating patients with acute ischemic…
- Trial name
- NCT07552818
- Testing
- Treatment with the I-NIC medical device for neuroprotection
- Volunteers
- 364 people
- Sponsor
- IGEA
Aneurysm, Dissection, Aortic
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
The goal of this observational study is to collect mid-term post-market clinical follow-up data of GORE® TAG® Thoracic Branch Endoprosthesis used according to the standard medical practice in patients presenting with vascular…
- Conditions
- Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
- Trial name
- NCT06507865
- Testing
- GORE® TAG® Thoracic Branch Endoprosthesis
- Where
- 19 sites in Austria, Denmark and 7 more
- Volunteers
- 155 people
- Sponsor
- W.L.Gore & Associates
Acute Leukemia, Chronic Myeloproliferative Disease
A Phase I Trial of ZIO-101 in Hematologic Cancers
This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical.
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma
- Trial name
- NCT00592046
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Congestive
A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Transient receptor potential vanilloid 4 (TRPV4) channel blockade may be promising in the treatment of pulmonary oedema and dyspnoea in heart failure (HF) and acute decompensated heart failure (ADHF) patients by re-establishing…
- Trial name
- NCT02135861
- Testing
- DCE-MRI scans, Gadobutrol
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Coronary Heart Disease
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
- Trial name
- NCT00134940
- Where
- 6 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Ischemic Stroke, Intracranial Stenosis
Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE)
Study objective is to evaluate the efficacy and safety of acute permanent stenting of symptomatic intracranial stenosis following unsuccessful recanalization by thrombectomy in acute ischemic stroke with large vessel occlusion…
- Trial name
- ACUTE (NCT03955835)
- Testing
- Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.
- Where
- 8 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Acandis GmbH
Stable Coronary Artery Disease, Acute Coronary Syndromes
Coronary Laser Atherectomy Registry From an International Taskforce
This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).
- Trial name
- CLARIT (NCT07348341)
- Testing
- Excimer Laser Coronary Atherectomy (ELCA)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Ceric Sàrl
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Myocardial Infarction
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.
- Trial name
- NCT00877903
- Testing
- Prochymal®
- Where
- 33 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Mesoblast, Inc.
Stroke
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
Research topic. A clinical trial of Danhong injection in treating acute ischemic stroke . Research purpose. To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke by a randomized, double-blind…
- Trial name
- NCT02152280
- Testing
- Danhong Injection, Normal Saline
- Volunteers
- 320 people
- Sponsor
- Beijing Bozhiyin T&S Co., Ltd.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi